We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI-Powered Tool Combs through Electronic Health Records For Faster Diagnoses of Rare Diseases

By HospiMedica International staff writers
Posted on 05 Jul 2024

A rare disease is defined as one that affects fewer than 200,000 individuals. More...

Collectively, over 10,000 known rare diseases impact more than 30 million people. While some of these diseases, like multiple sclerosis, are well-recognized, most—including bartonellosis, maple syrup urine disease, and visual snow syndrome—are not. Acute hepatic porphyria (AHP), a group of rare genetic disorders, affects 1 in 100,000 people, predominantly women. The symptoms often correlate with the menstrual cycle and can lead to severe, even life-threatening, episodes characterized by abdominal pain, nausea, vomiting, limb weakness, and anxiety. In 2019, the FDA approved givosiran as a prophylactic treatment for these recurrent attacks. However, the average time to diagnose AHP is 15 years, largely because physicians encounter it so infrequently. During this diagnostic delay, the disease can worsen and cause irreversible harm. Now, researchers have created an artificial intelligence (AI) tool that can identify potential patients with AHP, thus aiding in the diagnosis and management of this rare genetic disease.

This predictive algorithm developed by the team at UCLA Health (Los Angeles, CA, USA) under Project Zebra, sifts through electronic health records to spot patterns indicative of disease, alerting physicians to patients who may need further testing and diagnosis. It specifically targets suspected porphyria patients and was trained on a dataset that included de-identified patient records from UCSF and UCLA—part of approximately 10 million records throughout the UC system. The algorithm's development was complicated by the often lengthy approval process required for accessing patient data, and the fact that algorithms improve with access to vast datasets from various institutions, though obtaining the necessary permissions can be challenging. To overcome this, zebraMD has implemented Virtual Pooling, a patented technology that allows the algorithm to learn from data without actually transferring it.

One of the main hurdles in developing the algorithm was the unorganized nature of patient data, which includes both structured data, like vital signs and lab results, and unstructured data, such as physician's notes. The latter presents particular difficulties for algorithms, which prompted the researchers to refine and structure the data. The researchers equipped the model with detailed symptom information and references to a rare and genetic disease database maintained by the National Institutes of Health, which catalogs signs, symptoms, and clinical presentation of diseases including porphyria. The algorithm was then allowed to independently scan through the data and identify patterns, an approach that is crucial given the high rate of misdiagnosis associated with rare diseases. According to findings published in the Journal of the American Medical Informatics Association, the algorithm accurately predicted referrals for AHP testing with an accuracy between 89% and 93%, and it identified 71% of the patients who tested positive for the disease earlier than they were actually diagnosed, saving an average of 1.2 years per case. Currently, Project Zebra is expanding its focus to include predicting cerebral aneurysms, a potentially life-threatening condition characterized by the expansion of a weakened blood vessel in the brain.

“I hope that at some point this is a standard feature of any electronic health records system,” said Katharina “Kat” Schmolly, MD, a UCLA medical student who co-created the algorithm. “The more patients we can diagnose, the more we can monitor over time. That means we can learn what works and what doesn't work. We can create precision medicine approaches for these rare diseases. Many of them don't have any treatments yet. So hopefully, we can find new treatment options for them.”

Related Links:
UCLA Health


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Multi-Chamber Washer-Disinfector
WD 390
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image

Explainable AI Tool Improves Brain Disorder Screening from 4D fMRI

Functional magnetic resonance imaging (fMRI) captures changes in brain activity over time, but the resulting image sequences can be difficult to analyze. Screening for brain disorders requires assessing... Read more

Surgical Techniques

view channel
Image: Memo 4D Curve preserves the mitral annulus’s natural three-dimensional motion while supporting remodeling and is available in sizes up to 42 mm for a broad range of mitral pathology. (Photo courtesy of Corcym)

First Human Implant Performed With New Open Mitral Annuloplasty Ring

In mitral valve repair, clinicians aim to preserve the mitral annulus’s three-dimensional motion while providing enough support for effective remodeling. Ring preferences vary between open and closed ... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.